Single fraction carbon ion radiotherapy for colorectal cancer liver metastasis: A dose escalation study.


Journal

Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 24 08 2018
revised: 06 11 2018
accepted: 07 11 2018
pubmed: 13 11 2018
medline: 15 1 2019
entrez: 13 11 2018
Statut: ppublish

Résumé

Prognosis is usually grim for those with liver metastasis from colorectal cancer (CRC) who cannot receive resection. Radiation therapy can be an option for those unsuitable for resection, with carbon ion radiotherapy (CIRT) being more effective and less toxic than X-ray due to its physio-biological characteristics. The objective of this study is to identify the optimal dose of single fraction CIRT for colorectal cancer liver metastasis. Thirty-one patients with liver metastasis from CRC were enrolled in the present study. Twenty-nine patients received a single-fraction CIRT, escalating the dose from 36 Gy (RBE) in 5% to 10% increments until unacceptable incidence of dose-limiting toxicity was observed. Dose-limiting toxicity was defined as grade ≥3 acute toxicity attributed to radiotherapy. The prescribed doses were as follows: 36 Gy (RBE) (3 cases), 40 Gy (2 cases), 44 Gy (4 cases), 46 Gy (6 cases), 48 Gy (3 cases), 53 Gy (8 cases) and 58 Gy (3 cases). Dose-limiting toxicity was not observed, but late grade 3 liver toxicity due to biliary obstruction was observed in 2 patients at 53 Gy (RBE). Both cases had lesions close to the hepatic portal region, and, therefore, the dose was escalated to 58 Gy (RBE), limited to peripheral lesions. The 3-year actuarial overall survival rate of all 29 patients was 78%, and the median survival time was 65 months. Local control improved significantly at ≥53 Gy (RBE), with a 3-year actuarial local control rate of 82%, compared to 28% in lower doses. Treatment for CRC liver metastasis with single-fraction CIRT appeared to be safe up to 58 Gy (RBE) as long as the central hepatic portal region was avoided.

Identifiants

pubmed: 30417485
doi: 10.1111/cas.13872
pmc: PMC6317930
doi:

Types de publication

Clinical Trial, Phase I Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

303-309

Subventions

Organisme : National Institute of Radiological Sciences, Japan

Investigateurs

Shigeki Arii (S)
Ikuo Udagawa (I)
Masaak Ebara (M)
Takehito Otsubo (T)
Kiyoshi Ohara (K)
Takuji Okusaka (T)
Fumihiko Kanai (F)
Fukuo Kondo (F)
Akiko Saito (A)
Yoshiaki Shimizu (Y)
Kenichi Takayasu (K)
Jyunji Furuse (J)
Hiroshi Yamamoto (H)
Osamu Yokosuka (O)
Hiroyuki Yoshidome (H)
Hirohiko Tsujii (H)
Takehide Asano (T)
Ohkohchi Nobuhiro (O)
Masaharu Yoshikawa (M)
Takaaki Ikari (T)
Hirotoshi Kato (H)
Hiroshi Shimada (H)

Informations de copyright

© 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Références

Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1468-76
pubmed: 15275734
Dis Colon Rectum. 1982 Nov-Dec;25(8):749-54
pubmed: 7172942
Radiother Oncol. 2015 Nov;117(2):322-7
pubmed: 26385268
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1039-45
pubmed: 20888707
J Vasc Interv Radiol. 2003 Oct;14(10):1267-74
pubmed: 14551273
J Thorac Oncol. 2017 Apr;12(4):673-680
pubmed: 28007628
Radiat Oncol. 2015 Sep 17;10:187
pubmed: 26377092
Ann Surg Oncol. 2001 May;8(4):347-53
pubmed: 11352309
Gastrointest Cancer Res. 2007 Jan;1(1):20-7
pubmed: 19262699
Med Phys. 1995 Jan;22(1):37-53
pubmed: 7715569
Ann Surg. 2005 May;241(5):715-22, discussion 722-4
pubmed: 15849507
Br J Surg. 2010 Mar;97(3):377-82
pubmed: 20095016
Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):93-101
pubmed: 27375166
Cancer. 2017 Oct 15;123(20):3955-3965
pubmed: 28662297
Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7
pubmed: 15166961
Radiat Res. 1997 Jan;147(1):78-85
pubmed: 8989373
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
Ann Surg Oncol. 2016 Jan;23(1):218-24
pubmed: 25963478
Ann Surg. 2008 Jan;247(1):125-35
pubmed: 18156932
Ann Surg Oncol. 2011 Apr;18(4):1081-7
pubmed: 21046264
Cancer Sci. 2019 Jan;110(1):303-309
pubmed: 30417485
HPB (Oxford). 2015 May;17(5):387-93
pubmed: 25545319
J Clin Oncol. 2002 Nov 15;20(22):4466-71
pubmed: 12431970
Int J Radiat Oncol Biol Phys. 1991 Feb;20(2):203-6
pubmed: 1991679
Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):98-106
pubmed: 27979460
Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):241-50
pubmed: 10924995
J Am Coll Surg. 2010 May;210(5):744-52, 752-5
pubmed: 20421043
Acta Oncol. 2006;45(7):838-47
pubmed: 16982548
Radiat Oncol. 2014 Mar 01;9:68
pubmed: 24581481
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2125-31
pubmed: 21745719
Arch Surg. 2006 Jun;141(6):581-7; discussion 587-8
pubmed: 16785359
Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):1097-103
pubmed: 10863083
Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):201-10
pubmed: 10219815
Acta Med Okayama. 2015;69(4):219-26
pubmed: 26289913
Front Radiat Ther Oncol. 2004;38:100-5
pubmed: 15458194

Auteurs

Hirokazu Makishima (H)

National Institute of Radiological Sciences Hospital, National Institutes for Quantum and Radiological Sciences and Technology, Chiba, Japan.

Shigeo Yasuda (S)

National Institute of Radiological Sciences Hospital, National Institutes for Quantum and Radiological Sciences and Technology, Chiba, Japan.

Yuka Isozaki (Y)

National Institute of Radiological Sciences Hospital, National Institutes for Quantum and Radiological Sciences and Technology, Chiba, Japan.

Goro Kasuya (G)

National Institute of Radiological Sciences Hospital, National Institutes for Quantum and Radiological Sciences and Technology, Chiba, Japan.

Naomi Okada (N)

National Institute of Radiological Sciences Hospital, National Institutes for Quantum and Radiological Sciences and Technology, Chiba, Japan.

Masaru Miyazaki (M)

Mita Hospital, International University of Health and Welfare, Tokyo, Japan.

Osama Mohamad (O)

National Institute of Radiological Sciences Hospital, National Institutes for Quantum and Radiological Sciences and Technology, Chiba, Japan.
University of Texas Southwestern Medical center, Dallas, Texas.

Naruhiro Matsufuji (N)

National Institute of Radiological Sciences Hospital, National Institutes for Quantum and Radiological Sciences and Technology, Chiba, Japan.

Shigeru Yamada (S)

National Institute of Radiological Sciences Hospital, National Institutes for Quantum and Radiological Sciences and Technology, Chiba, Japan.

Hiroshi Tsuji (H)

National Institute of Radiological Sciences Hospital, National Institutes for Quantum and Radiological Sciences and Technology, Chiba, Japan.

Tadashi Kamada (T)

National Institute of Radiological Sciences Hospital, National Institutes for Quantum and Radiological Sciences and Technology, Chiba, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH